Abstract
The expression of the death receptor Fas/CD95 is cell type-specific and can be modulated by different cytotoxic treatments. In spite of a frequent expression of Fas/CD95 in high-grade gliomas, these tumours are typically refractory to conventional therapy. Using a human glioblastoma cell line (GBM), we explored the possibility of modulating susceptibility to Fas/CD95-mediated apoptosis following cytotoxic treatment. GBM cells were sensitive to the antiproliferative effects of topoisomerase I inhibitors (topotecan and a novel lipophilic analog CPT83) and taxol, less sensitive to cisplatin and, in any case, rather resistant to drug-induced apoptosis. This pattern of cellular response was consistent with p53 mutation. GBM cells expressed low levels of Fas/CD95, which was associated with low susceptibility to antibody-stimulated Fas/CD95-mediated apoptosis. A significant up-regulation of Fas/CD95 expression was detected after exposure to topotecan and CPT83, whereas cisplatin induced a low increase and taxol did not modify Fas/CD95 expression. In addition, after treatment with topoisomerase I inhibitors, the up-regulation of Fas/CD95 resulted in an increased susceptibility of GBM cells to antibody-stimulated Fas/CD95-mediated apopt...Continue Reading
References
Mar 26, 1992·Nature·R Watanabe-FukunagaS Nagata
Sep 1, 1994·The Journal of Clinical Investigation·M WellerA Fontana
May 1, 1995·Scandinavian Journal of Immunology·F SpinozziR Vaccaro
Jan 1, 1994·Journal of Cancer Research and Clinical Oncology·P PeregoC Soranzo
May 3, 1996·International Journal of Cancer. Journal International Du Cancer·R MarchesiniF Zunino
Jun 1, 1996·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J A Hickman
May 1, 1997·British Journal of Haematology·D WangM J Robertson
Nov 5, 1997·Nature Genetics·M Kastan
Apr 2, 1998·Cancer Chemotherapy and Pharmacology·S RomanelliF Zunino
Apr 16, 1998·Pharmacology & Therapeutics·F ZuninoF Arcamone
Jun 24, 1998·Cell and Tissue Research·M Weller
Jun 10, 1998·Current Opinion in Oncology·S A Rempel
Jul 29, 1998·International Journal of Cancer. Journal International Du Cancer·U Naumann, M Weller
Sep 28, 1998·Biochimica Et Biophysica Acta·Y PommierD Strumberg
Dec 8, 1998·International Journal of Cancer. Journal International Du Cancer·M WellerJ Dichgans
Jan 8, 2000·International Reviews of Immunology·J R OrlinickK B Elkon
Feb 8, 2000·The Journal of Biological Chemistry·D MunschP Reisdorf
Apr 1, 2000·Journal of Neuroimmunology·S FrigerioA Salmaggi
Apr 19, 2000·Cancer Gene Therapy·N ShinouraH Hamada
Oct 29, 2000·Journal of Medicinal Chemistry·S DallavalleF Zunino
Citations
Jul 3, 2008·Cancer Immunology, Immunotherapy : CII·Jun WeiAmy B Heimberger
Dec 15, 2007·Neuro-oncology·Amy B HeimbergerJohn H Sampson
Sep 26, 2012·Biochimica Et Biophysica Acta·Maja T Tomicic, Bernd Kaina
Jan 28, 2006·Biochemical Pharmacology·Paola PeregoFranco Zunino
Sep 28, 2005·Journal of Neuro-oncology·Erik D FoehrRoman Urfer
Jun 3, 2020·Nanomedicine·James J HobsonNeill J Liptrott
Feb 19, 2005·Journal of Neuro-oncology·Emilio CiusaniAndrea Salmaggi
Aug 19, 2007·Molecular Cancer Research : MCR·Shuli XiaJohn Laterra
Feb 19, 2008·Cancer Research·Tanja HerrmannGundram Jung
Jun 17, 2005·Cancer Research·Shuli XiaJohn Laterra